| Literature DB >> 29692810 |
Claudio Casella1, Sarah Molfino2, Francesco Mittempergher2, Carlo Cappelli3, Nazario Portolani2.
Abstract
OBJECTIVE: Aim of this study is to evaluate determinants of secondary normocalcemic hyperparathyroidism (SNHPT) persistence in patients who have undergone Roux-en-Y gastric bypass on vertical-banded gastroplasty.Entities:
Year: 2018 PMID: 29692810 PMCID: PMC5859829 DOI: 10.1155/2018/5010287
Source DB: PubMed Journal: Int J Endocrinol ISSN: 1687-8337 Impact factor: 3.257
Figure 1Study design.
Inclusion and exclusion criteria for eligibility of the study.
| Inclusion criteria | Exclusion criteria |
|---|---|
| Age between 18 and 60 years | Currently using pharmacological (e.g., hormone replacement therapy) or supplementation treatment to influence VD metabolism |
| Caucasian ethnicity | Disease influencing calcium metabolism, polyendocrinopathy or autoimmune disease and other causes of secondary hyperparathyroidism∗ |
| BMI >40 kg/m2 or 35–40 kg/m2 with obesity-associated comorbidity | History of cancer |
| Availability and willingness to comply with 18-month outpatient follow-up | Prior head or neck surgery |
| Availability and willingness to have blood samples tested for calcium, 25-hydroxy vitamin D, and PTH levels. | Prior abdominal or bariatric surgery |
| Availability to take oral supplements, if needed | Lack of calcium metabolism documentation |
| Normal preoperative renal function | Lost to follow-up |
∗Causes of secondary hyperparathyroidism according to Fraser [22]: (i) steroid therapy; (ii) patients overclothing; (iii) bisphosphonate therapy; (iv) osteolytic lesions; (v) diuretic therapy; (vi) previous acute pancreatitis; (vii) state of sepsis; (viii) chronic kidney disease and hypercalciuria; (ix) intake of drugs that interact with vitamin D (e.g., phenobarbital and phenytoin); and (x) use of antacids containing aluminum that interfere with phosphate absorption.
Figure 2Extra weight defined according to Lorentz formula.
Presurgical anthropometric and laboratory variables of study group (n = 226).
| Variable | Mean ± SD |
|---|---|
| Age (years) | 37 ± 9.09 |
| BMI (kg/m2) | 44.34 ± 5.06 |
| Elapsed time since last effective diet (years) | 9 ± 1.05 |
| 25-hydroxy vitamin D (ng/mL) | 25.3 ± 4.25 |
| Serum calcium (mg/dL) | 9.18 ± 2.01 |
| Serum PTH (pg/dL) | 81.48 ± 3.45 |
Demographic and laboratory characteristics of presurgical SNHPT patients (group 1, n = 201) and nonpresurgical SNHPT (group 2, n = 25) patients.
| Presurgical variable | Group 1 | Group 2 |
|
|---|---|---|---|
| Age (years, mean ± SD) | 31.5 ± 3.5 | 35.5 ± 2.8 | 0.123 |
| BMI (kg/m2, mean ± SD) | 43.4 ± 4.5 | 39 ± 6.7 | 0.103 |
| Elapsed time since last effective diet (years, mean ± SD) | 8.5 ± 0.5 | 4 ± 1.2 | <0.05 |
| Serum 25-hydroxy vitamin D (ng/mL, mean ± SD) | 23.8 ± 2.6 | 29 ± 1.8 | <0.05 |
| Serum calcium (mg/dL, mean ± SD) | 9 ± 1.8 | 9 ± 2.1 | 0.456 |
| Serum PTH (pg/dL, mean ± SD) | 78.8 ± 3.2 | 63 ± 5.4 | <0.05 |
∗ANOVA for continuous variables.
Anthropometric and laboratory values during follow-up: group 3 patients (n = 153) recovered from SNHPT within 6 months after surgery and group 4 patients (n = 48) within 18 months; group 2 patients (n = 25) without presurgical SNHPT.
| Variable | Group 4 | Group 3 |
| Group 2 | |
|---|---|---|---|---|---|
| 6 months | Serum 25-hydroxy vitamin D (ng/mL, mean ± SD) | 25.5 ± 2.5 | 35.6 ± 1.8 |
| 37.1 ± 3.1 |
| Serum calcium (mg/dL, mean ± SD) | 9.1 ± 1.0 | 9.08 ± 1.1 |
| 9.1 ± 1.7 | |
| Serum PTH (ml/dL, mean ± SD) | 74.56 ± 5.2 | 50.7 ± 3.5 | <0.05 | 49.3 ± 2.5 | |
| Elapsed time since last effective diet (years, mean ± SD) | 12 ± 1.5 | 5 ± 0.5 | <0.05 | 4 ± 1.2 | |
| Extra weight-loss percentage (%EWL, mean ± SD) | 44.1 ± 2.5 | 40.3 ± 2.2 | <0.05 | 38.9 ± 1.8 | |
|
| |||||
| 12 months | Serum 25-hydroxy vitamin D (ng/mL, mean ± SD) | 26.4 ± 3.2 | 42.4 ± 1.7 |
| 46.1 ± 1.3 |
| Serum calcium (mg/dL, mean ± SD) | 9.3 ± 0.5 | 9.08 ± 0.9 |
| 9.1 ± 1.1 | |
| Serum PTH (mg/dL, mean ± SD) | 73 ± 3.2 | 43.1 ± 3.3 | <0.05 | 45.6 ± 1.4 | |
| Extra weight loss percentage (%EWL, mean ± SD) | 54.3 ± 1.5 | 46.6 ± 3.1 | <0.05 | 46.5 ± 1.9 | |
|
| |||||
| 18 months | Serum 25-hydroxy vitamin D (ng/mL, mean ± SD) | 32.1 ± 0.9 | 43.7 ± 1.2 |
| 46.3 ± 1.9 |
| Serum calcium (mg/dL, mean ± SD) | 9.8 ± 1.1 | 9.6 ± 2.0 |
| 9.4 ± 1.1 | |
| Serum PTH (mg/dL, mean ± SD) | 56.6 ± 2.2 | 40.3 ± 1.5 | <0.05 | 39.1 ± 0.5 | |
| Extra weight loss percentage (%, mean ± SD) | 65.3 ± 2.6 | 59.1 ± 3.2 | <0.05 | 59.6 ± 2.8 | |
∗ANOVA for continuous variables; N.S. not statistically significant.
Figure 3Extra weight loss percentage (EWL%) in the group 3 patients (n = 153) recovered from SNHPT within 6 months after surgery and group 4 patients (n = 48) within 18 months.
Figure 4Serum parathyroid hormone levels in group 3 patients (n = 153) recovered from SNHPT within 6 months after surgery and group 4 patients (n = 48) within 18 months.